Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Royal Holloway And Bedford New College has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, Alexandra Rose Lippolis, in 1 distinct art unit. Alexandra Rose Lippolis is the busiest examiner, managing 1 pending office action. Since there is only 1 pending action, the entire current workload is centralized with this examiner. This suggests a narrow scope of current examination activity for the institution's biotechnology patent applications.
The involvement of 1 distinct examiner and 1 distinct art unit means that the 1 pending office action is subject to a single set of examination criteria. Because Alexandra Rose Lippolis is the only examiner currently active for the institution, her individual approach will define the immediate results. This centralized structure in the Biotechnology & Pharmaceuticals sector provides a clear and predictable path for the institution's intellectual property. Practitioners can efficiently manage this portfolio by focusing on the specific standards and history of the 1 distinct examiner involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIPPOLIS, ALEXANDRA ROSE | 1 | 46.9% | +59.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17762355 | Methods of Treatment of Neurofibromatosis Type 1 (NF1) and NF-1 Mediated Conditions and Compositions for Use in Such Methods | LIPPOLIS, ALEXANDRA ROSE | 35d overdue |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17762355 | Methods of Treatment of Neurofibromatosis Type 1 (NF1) and NF-1 Mediated Conditions and Compositions for Use in Such Methods | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103 | Non-Final OA | 35d overdue | Pending | Mar 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial